SCHEMBL20525005

SCHEMBL20525005

O=C(OCc1ccccc1)c1cccc(C2CC2C(=O)Nc2ccc3cnccc3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 19/20 0.56
▸ ROCK1 Q13464 16/20 0.56
▸ JAK2 O60674 13/20 0.56
▸ JAK3 P52333 12/20 0.56
▸ IKBKB O14920 8/20 0.56
▸ JAK1 P23458 5/20 0.51
▸ TYK2 P29597 5/20 0.51
▸ TNF P01375 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22751944 1.00 ROCK2 (0.56) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL22752134 0.91 ROCK2 (0.63) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL20524961 0.91 ROCK2 (0.63) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL29728121 0.91 ROCK2 (0.63) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL20353559 0.86 ROCK2 (0.59) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL22752067 0.86 ROCK2 (0.59) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL22752051 0.86 ROCK2 (0.56) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL22751899 0.86 ROCK2 (0.51) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL21774943 0.85 ROCK2 (0.63) ROCK2ROCK1JAK2JAK3IKBKB
SCHEMBL20525007 0.85 ROCK2 (0.63) ROCK2ROCK1JAK2JAK3IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2023-04-27 — — US disclosed
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2023-04-27 — — US disclosed
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2023-04-27 — — US disclosed
US-11312700-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2022-04-26 — — US disclosed
US-20210002253-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2021-01-07 — — US disclosed
US-10858339-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2020-12-08 — — US disclosed
EP-3609871-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS Aerie Pharmaceuticals, Inc. (US) 2020-02-19 — — EP disclosed
WO-2018183911-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS AERIE PHARMACEUTICALS, INC. (US) 2018-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002253-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS UACA, HRAS, MYLK ROCK2 219/4885ROCK1 278/4885JAK2 268/4885
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK ROCK2 219/4885ROCK1 278/4885JAK2 268/4885
US-11312700-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK ROCK2 219/4885ROCK1 278/4885JAK2 268/4885
US-10858339-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK ROCK2 219/4885ROCK1 278/4885JAK2 268/4885
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS UACA, HRAS, MYLK ROCK2 219/4885ROCK1 278/4885JAK2 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback